CROI (Conference on Retroviruses and Opportunistic Infections)

The Latest

New Study Shows Women's HIV Risk Triples During Pregnancy, Quadruples Postpartum

Study highlights the need for PrEP and other HIV prevention strategies for pregnant women and new mothers in high-prevalence settings.

By Sony Salzman

More Women Must Be Included in Academia and in Clinical Trials, Panelists Demand

Presentations on women in research at this year's Conference on Retroviruses and Opportunistic Infections highlighted the lack of inclusion, offered ideas on how to remedy the situation, and showed how one woman moved from advocate to researcher.

By Barbara Jungwirth

Final HIV Research Highlights From CROI 2018

Two video interviews with federal HIV leaders who share their perspectives about the science coming out of the conference and its implications for HIV prevention, care, and treatment.

By HIV.gov

CDC: Few People Who Could Benefit From PrEP Are Using It

The CDC has released new data at the Conference on Retroviruses and Opportunistic Infections (CROI) estimating that only a small percentage of people most at risk for HIV infection have actually been prescribed pre-exposure prophylaxis (PrEP).

By Kenyon Farrow

Separate and Unequal Access Frames Discussion at CROI Panel on U.S. HIV Care Cascade

The lack of Medicaid expansion in the South is creating worse racial disparities in the U.S., according to researchers and medical providers discussing the HIV care cascade at CROI 2018.

By Kenyon Farrow

More HIV Research Highlights From CROI 2018

Three video interviews with federal HIV leaders who shared perspectives about the science coming out of the conference and its implications for HIV prevention, care, and treatment.

By HIV.gov

Inching Towards an HIV Cure: bNAb and TLR-7 Agonist Reduce Viral Rebound Off-ART in Macaques

Results from a proof-of-principle study in macaques showing that treatment with broadly neutralising antibodies might play a role in key stages for an HIV cure.

By Simon Collins for HIV i-Base

Bictegravir at CROI 2018: Switching Studies and Drug Resistance Analyses

Reports about bictegravir, the most recently approved integrase inhibitor, were included in an oral presentation and in several posters at CROI 2018.

By Simon Collins for HIV i-Base

Dual Therapy Can Reduce TB Prophylaxis From Nine Months to One: Fewer Side Effects and More People Complete Treatment

New results presented at CROI 2018 from a large international study using a simplified approach to prevent TB have the potential to dramatically improve outcomes for HIV positive people.

By Simon Collins for HIV i-Base

Twice-Daily Dolutegravir Is Effective and Tolerable With Rifampicin

24-week interim results from the INSPIRING study presented at CROI 2018 show that dolutegravir 50 mg twice daily is effective and well-tolerated in adults with HIV/TB receiving rifampicin-based TB treatment.

By Polly Clayden for HIV i-Base